Skip to main content

Using Genome-Editing Tools to Develop a Novel In Situ Coincidence Reporter Assay for Screening ATAD3A Transcriptional Inhibitors

  • Protocol
  • First Online:
Clinical and Preclinical Models for Maximizing Healthspan

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2138))

Abstract

Transgene-based reporter gene assays have been used for discovery of inhibitors targeting vital gene transcription. In traditional assays, the reporter gene is commonly fused with a cloned promoter and integrated into a random genomic location. This has been widely applied but significantly dampened by disadvantages, including incomplete cis-acting elements, the influence of foreign epigenetic environments, and generation of false hits that disrupt the luciferase reporter activity. Therefore, there is a need to develop novel strategies for developing in situ reporter assays closely mimicking endogenous gene expression without disrupting its function. By employing the CRISPR-Cas9 system, we developed an effective in situ coincidence reporter system with a selection marker in the endogenous locus of ATAD3A, which provides a means of screening for transcription-targeted lead compounds with high confidence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chau N-M, Rogers P, Aherne W, Carroll V, Collins I, McDonald E et al (2005) Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1α induction in response to hypoxic stress and growth factors. Cancer Res 65(11):4918–4928

    Article  CAS  Google Scholar 

  2. Lang L, Ding H-F, Chen X, Sun S-Y, Liu G, Yan C (2015) Internal ribosome entry site-based bicistronic in situ reporter assays for discovery of transcription-targeted lead compounds. Chem Biol 22(7):957–964

    Article  CAS  Google Scholar 

  3. Dansithong W, Paul S, Scoles DR, Pulst SM, Huynh DP (2015) Generation of SNCA cell models using zinc finger nuclease (ZFN) technology for efficient high-throughput drug screening. PLoS One 10(8):e0136930. https://doi.org/10.1371/journal.pone.0136930

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hasson SA, Fogel AI, Wang C, MacArthur R, Guha R, Heman-Ackah S et al (2015) Chemogenomic profiling of endogenous PARK2 expression using a genome-edited coincidence reporter. ACS Chem Biol 10(5):1188–1197

    Article  CAS  Google Scholar 

  5. Yang W, Zhang S, Zhang Y, Huang X (2017) A novel strategy to dissect endogenous gene transcriptional regulation in live cells. Biochem Biophys Res Commun 487(3):573–579

    Article  CAS  Google Scholar 

  6. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8(11):2281–2308

    Article  CAS  Google Scholar 

  7. Auld DS, Southall NT, Jadhav A, Johnson RL, Diller DJ, Simeonov A et al (2008) Characterization of chemical libraries for luciferase inhibitory activity. J Med Chem 51(8):2372–2386

    Article  CAS  Google Scholar 

  8. Cheng KC, Inglese J (2012) A coincidence reporter-gene system for high-throughput screening. Nat Methods 9(10):937. https://doi.org/10.1038/nmeth.2170

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Schuck BW, MacArthur R, Inglese J (2017) Quantitative high-throughput screening using a coincidence reporter biocircuit. Curr Protoc Neurosci 79:5.32.1–5.32.27. https://doi.org/10.1002/cpns.27

    Article  CAS  Google Scholar 

  10. Teng Y, Ren X, Li H, Shull A, Kim J, Cowell JK (2016) Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein. Oncogene 35(3):333–343

    Article  CAS  Google Scholar 

  11. Dickerson T, Jauregui CE, Teng Y (2017) Friend or foe? Mitochondria as a pharmacological target in cancer treatment. Future Med Chem 9(18):2197–2210

    Article  CAS  Google Scholar 

  12. Fang H-Y, Chang C-L, Hsu S-H, Huang C-Y, Chiang S-F, Chiou S-H et al (2010) ATPase family AAA domain-containing 3A is a novel anti-apoptotic factor in lung adenocarcinoma cells. J Cell Sci 123(Pt 7):1171–1180

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by NIH grant R03DE028387 and R01DE028351 (to Y.T.).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yong Teng .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Lang, L., Teng, Y. (2020). Using Genome-Editing Tools to Develop a Novel In Situ Coincidence Reporter Assay for Screening ATAD3A Transcriptional Inhibitors. In: Guest, P. (eds) Clinical and Preclinical Models for Maximizing Healthspan. Methods in Molecular Biology, vol 2138. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0471-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0471-7_8

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0470-0

  • Online ISBN: 978-1-0716-0471-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics